Generic Name: vorinostat
Drug Class: Chemotherapy Medications
Company: Merck
Approval Status: Approved
Generic Version Available: No
Drug Indication
Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.
General Info
Zolinza is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.
Dosage
Dosing Info:
Zolinza is a capsule taken once daily with food.
Side Effects
Common side effects include diarrhea, fatigue, nausea and loss of appetite. Zolinza can cause depletion of red blood cells (anemia) and platelets (thrombocytopenia), which can lead to easy bleeding. Potential severe side effects include blood clots, gastrointestinal damage and high blood glucose. Zolinza may cause fetal harm if used during pregnancy.
For More Info: https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf
Patient Assistance Program Info: http://www.merckhelps.com/ZOLINZA
Last Reviewed: November 29, 2018
